The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.
Please refer to the following website for further details:
Rivoceranib’s combined clinical results will be known at IASLC 2022: HLB < Pharma < 기사본문 - KBR
